The short version of trans-3-hexenoyl fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
==== Chromogenic microbiological media ==== Chromogenic microbiological media use colored enzymes to detect the presence of certain bacteria. In conventional bacteria culturing, bacteria are allowed to grow on a medium that supports many strains. Since it is hard to isolate bacteria, many cultures of different bacteria are able to form. To identify a particular bacteria culture, scientists must identify it using only its physical characteristics. Then further tests can be performed to confirm the presence of the bacteria, such as serology tests that find antibodies formed in organisms as a response to infection. In contrast, chromogenic microbiological media use particular color-producing enzymes that are targeted for metabolism by a certain strain of bacteria. Thus, if the given cultures are present, the media will become colored accordingly as the bacteria metabolize the color-producing enzyme. This greatly facilitates the identification of certain bacteria cultures and can eliminate need for further testing. To guard against misidentification of bacteria, the chromogenic plates typically incorporate additional enzymes that will be processed by other bacteria. Now, as the non-target bacteria interact with the additional enzymes, they will produce colors that distinguish them from the target bacteria.
=== Natural sources === Glycerol is generally obtained from plant and animal sources where it occurs in triglycerides: esters of glycerol with long-chain carboxylic acids. The hydrolysis, saponification, or transesterification of these triglycerides produces glycerol as well as the fatty acid derivative:
== Awards and honors == Distinguished Mentor Award (University of Utah) 2019 University of Utah MUSE Professor 2019-ongoing Presidential Scholar Award (University of Utah) 2016–2019 Teva Pharmaceutical Scholar Award 2015–2018 Young Investigator Award, Metals in Medicine Gordon Conference 2012 Fellow of the American Association for the Advancement of Science 2023
=== Bill Adler === Bill Adler (Trevor White) is the global head of FICC (Fixed Income, Currencies and Commodities) at Pierpoint, and is based out of the New York headquarters. Adler is a ruthless pragmatist fiercely devoted to the firm; he is also a longtime friend of Eric, who initially hired him, but as his senior, he is shown to feel entitled to Eric's loyalty and support. Adler first appears in the series 1 finale to vet new grads on the RIF day. He makes Harper a deal to reinstate Eric after she got him fired for his verbal abuse in the workplace. In series 2, Eric visits Adler in New York following the loss of Felim Bichan as a client and confronts him over reduced compensation for his team and the rumored consolidation of the London and New York desks. Adler rebuffs Eric, citing his underperformance, and sidelines him in a non-trading role. DVD later goes to Adler to report client Nicole Craig's sexual assault of new hire Venetia Berens, but Adler tells him to bury the case. When Harper and Eric go to Adler proposing a leaner London office and threaten to publicize Pierpoint's culture of suppression, Adler accepts their terms, consolidating CPS and FX and allowing DVD to be dismissed. In series 3, Adler supports Eric’s promotion to partner but orders him to fire a trader to demonstrate authority, leading Eric to dismiss Kenny Kilbane. Adler intervenes directly on the trading floor during the Lumi IPO to reassure investors.
A typical baby bottle has four components: the first is the main container or body of the bottle. A teat, or nipple, is the flexible part of the bottle that the baby will suck from, and contains a hole through which the milk will flow. The collar goes over the nipple and typically screws onto the neck of the bottle, forming a seal. Most, but not all baby bottles will also have a cap or travel cover that goes over the teat to keep it clean and to prevent small spills. Some bottles may optionally have a disposable liner. Design concerns for the making of baby bottles often reflect safety or comfort. A safe baby bottle should not break, should not come apart easily into small or potentially harmful components, should not be made of materials that pose a health risk, and should be easy to clean so as to avoid bacterial contamination and illness. A bottle should also be comfortable for both caregiver and baby to use. Bottles that are lightweight and easy to hold can be desired by both babies and mothers. A variety of shapes are available. The design of containers, nipples or teats may mimic the shape of the mother's breast. Designers may try to mimic the flow rate of breastfeeding: the baby should be able to get enough nourishment, but at the same time not be overwhelmed or overfed.
Sources: en.wikipedia.org
==== 2016: Redshirt season ==== Following his matriculation at the University of Oregon in the spring of 2016, McCormick redshirted his freshman season while recovering from his knee injury. By August 2016, McCormick had been cleared to fully participate in football activities, though he was required to wear a knee brace. In September 2016, McCormick told The Oregonian that the brace may be blunting his speed, owing to the brace's impact on his natural running motion.
The company's Advanced Technology Investment Company (ATIC) in 2008, is an investment company in the high-technology sector. ATIC owns the semiconductor foundry companies GlobalFoundries, and Chartered Semiconductor Manufacturing (which later merged with GlobalFoundries). ATIC has invested in Calxeda, a start-up company for producing ARM architecture–based computers for the server market. In 2011, ATIC announced investments of $5.5 billion to expand chip manufacturing in Singapore, Dresden, and New York. It also announced a $6–$8 billion computer chip factory in Abu Dhabi for completion in 2012. The company supports research initiatives in Khalifa University, UAE University, American University of Sharjah, Masdar Institute and New York University Abu Dhabi. In 2014, ATIC became Mubadala Technology.
=== Redox === p-Hydroxybenzoate hydroxylase (PHBH) catalyzes the oxygenation of p-hydroxybenzoate (pOHB) to 3,4-dihyroxybenzoate (3,4-diOHB); FAD, NADPH and molecular oxygen are all required for this reaction. NADPH first transfers a hydride equivalent to FAD, creating FADH−, and then NADP+ dissociates from the enzyme. Reduced PHBH then reacts with molecular oxygen to form the flavin-C(4a)-hydroperoxide. The flavin hydroperoxide quickly hydroxylates pOHB, and then eliminates water to regenerate oxidized flavin. An alternative flavin-mediated oxygenation mechanism involves the use of a flavin-N(5)-oxide rather than a flavin-C(4a)-(hydro)peroxide.
The third major group of regulatory RNAs is called enhancer RNAs. It is not clear at present whether they are a unique category of RNAs of various lengths or constitute a distinct subset of lncRNAs. In any case, they are transcribed from enhancers, which are known regulatory sites in the DNA near genes they regulate. They up-regulate the transcription of the gene(s) under control of the enhancer from which they are transcribed.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.